20-21 Alzheimer’s disease – the future of diagnosis and treatment in Europe
CAR-Ts pose a unique challenge for healthcare systems, exacerbated by uncertainty around their long-term, real-world value
Thought Leadership, 18 December 2025
Thermo Fisher Scientific’s Martin Danielson talks to PME; Celebrating the 2025 PMEAs; Redefining the prostate cancer landscape

ESMO celebrates 50 years of focusing on oncology research; Improving cardiovascular disease therapy; Global pharma pricing impact on supply chains

Explore the 'Patient Metro' journey, the pillars of Alzheimer's blood testing, and how to de-risk clinical trials with platelet analysis for improved healthcare outcomes.

Will data and AI transform launch excellence? The impact of us tariffs on healthcare and life sciences; The power of digital and AI engineering

Full coverage of this year’s Communiqué Awards; The importance of patient engagement; Cannes Lions 2025 highlights

Communicating with HCPs through AI; ASCO 2025 highlights; The impact of US tariffs on pharma manufacturing

Rising to meet the challenges of clinical trials; Accelerating access to rare disease treatments; Maximising the potential of AI in pharma

How HCPs and patients are partnering to transform care; The impact of MS on ageing patients; AI in healthcare

PMLiVE’s Top Pharma List is live!; Omnichannel – breaking down the barriers; Rare diseases – improving patient access

Achieving inclusivity for minorities in clinical trials; Why local knowledge is key for pharmacovigilance; EU vs US trends in clinical trials

Avalere Health’s Amar Urhekar on his career path; Insights from ASH 2024; The science behind gene-silencing technology

Sanofi’s John Forni on the escalating challenges of treating COPD; The need for a human touch in an AI world; PMGroup celebrates the 24th PMEAs!

The explosive growth of Gen AI; Liberating patient pathways; Closing health equity gaps

Boehringer Ingelheim’s Ulrike Graefe-Mody on her career path; Driving launch excellence; Top trends coming out of ESMO 2024

The challenges of environmental sustainability; ‘Causes That Count, Health’ report; Rethinking neurodegeneration

Merck’s Doina Ionescu on her professional journey; Full coverage of Communiqué 2024; Omnichannel opportunities

GSK’s Jack Harris on innovation in oncology; Harnessing creativity in a digital age; Sustainability in pharma

Interview with Ipsen’s Ioana Parsons on her new role; Celebrating comms excellence; Getting trial diversity right

Astellas' Marci English on managing the menopause; Clinigen’s Lorna Pender on treating rare diseases; the science behind behaviour change

Interview with Sanofi’s Rippon Ubhi on her new role; Optimising MS care and patient outcomes; Overcoming pharma web strategy challenges

Diversity, equity and inclusion in medical research; Marking International Day of Women and Girls in Science; Incentivising innovation in antibiotics

CAR-Ts pose a unique challenge for healthcare systems, exacerbated by uncertainty around their long-term, real-world value
Thought Leadership, 18 December 2025
CAR-Ts pose a unique challenge for healthcare systems, exacerbated by uncertainty around their long-term, real-world value
Thought Leadership, 18 December 2025



CAR-Ts pose a unique challenge for healthcare systems, exacerbated by uncertainty around their long-term, real-world value
Thought Leadership, 27 November 2025
Roche and Ascidian agree to $1.8bn neurological disease partnership


How much time do you spend thinking about the impact of what is working and what is not in today’s organisational reality, versus what was captured in the situational analysis in your brand plan?

Researchers identify new major cause of inflammatory bowel disease


How much time do you spend thinking about the impact of what is working and what is not in today’s organisational reality, versus what was captured in the situational analysis in your brand plan?

Collecting the right data in the right way for the right reasons

The evolutionary lessons for Bayer’s management restructure

Researchers identify new major cause of inflammatory bowel disease

Roche and Ascidian agree to $1.8bn neurological disease partnership


How much time do you spend thinking about the impact of what is working and what is not in today’s organisational reality, versus what was captured in the situational analysis in your brand plan?

Collecting the right data in the right way for the right reasons

The evolutionary lessons for Bayer’s management restructure

UCB’s Bimzelx approved by MHRA for hidradenitis suppurativa

Researchers identify new major cause of inflammatory bowel disease


Picking your omnichannel direction requires a disciplined, scientific approach
Features, 18 December 2025
Across almost every sector, brands are multiplying their investment in creativity
Features, 18 December 2025

Picking your omnichannel direction requires a disciplined, scientific approach
Features, 18 December 2025
Across almost every sector, brands are multiplying their investment in creativity
Features, 18 December 2025


‘Patient engagement is both a process and a behaviour throughout the drug life cycle’
Communique - Marketing & Comms, 18 December 2025







